Conclusion
Molecular imaging holds strong promise for early and sensitive diagnosis of thromboembolic diseases. The choice of epitopes and biomarkers for molecular targeting, as well as the selection of imaging modalities and their respective contrast agents, are especially important for clinical translation. A better understanding of thrombotic diseases and their progression will provide the clinicians with information to determine the pharmacological treatment most suited for an individual, taking us closer towards personalised medicine. Furthermore, the ability to determine the success or failure of antithrombotic or fibrinolytic treatment will also enable better decisions for invasive interventions to be performed. Therefore, molecular imaging of thrombi has an enormous potential to provide benefits for patients suffering from thromboembolic diseases.